Browse by author
Lookup NU author(s): Professor Anthony MoormanORCiD, Professor Christine Harrison FRCPath FMedSci
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2018 Macmillan Publishers Limited, part of Springer Nature The R98S mutation in ribosomal protein L10 (RPL10 R98S) affects 8% of pediatric T-cell acute lymphoblastic leukemia (T-ALL) cases, and was previously described to impair cellular proliferation. The current study reveals that RPL10 R98S cells accumulate reactive oxygen species which promotes mitochondrial dysfunction and reduced ATP levels, causing the proliferation defect. RPL10 R98S mutant leukemia cells can survive high oxidative stress levels via a specific increase of IRES-mediated translation of the anti-apoptotic factor B-cell lymphoma 2 (BCL-2), mediating BCL-2 protein overexpression. RPL10 R98S selective sensitivity to the clinically available Bcl-2 inhibitor Venetoclax (ABT-199) was supported by suppression of splenomegaly and the absence of human leukemia cells in the blood of T-ALL xenografted mice. These results shed new light on the oncogenic function of ribosomal mutations in cancer, provide a novel mechanism for BCL-2 upregulation in leukemia, and highlight BCL-2 inhibition as a novel therapeutic opportunity in RPL10 R98S defective T-ALL.
Author(s): Kampen KR, Sulima SO, Verbelen B, Girardi T, Vereecke S, Rinaldi G, Verbeeck J, Op de Beeck J, Uyttebroeck A, Meijerink JPP, Moorman AV, Harrison CJ, Spincemaille P, Cools J, Cassiman D, Fendt S-M, Vermeersch P, de Keersmaecker K
Publication type: Article
Publication status: Published
Journal: Leukemia
Year: 2018
Volume: 33
Issue: 2
Pages: 319-322
Print publication date: 01/02/2019
Online publication date: 21/06/2018
Acceptance date: 21/05/2018
ISSN (print): 0887-6924
ISSN (electronic): 1476-5551
Publisher: Nature Publishing Group
URL: https://doi.org/10.1038/s41375-018-0176-z
DOI: 10.1038/s41375-018-0176-z
Altmetrics provided by Altmetric
